All In MedTech

FDA Clearance Tracker · P940016-S014

HEPARIN-INDUCED EXTRACORPOREAL LIPOPROTEIN PRECIPITATION (H.E.L.P.) FUTURA APHERESIS SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 13, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P940016-S014
Device name
HEPARIN-INDUCED EXTRACORPOREAL LIPOPROTEIN PRECIPITATION (H.E.L.P.) FUTURA APHERESIS SYSTEM
Applicant location
Melsungen
Received
Jul 19, 2011
Decided
Jan 13, 2012
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P940016

Device type

Device class
Class III

Every decision under product code MMY

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A CHANGE IN THE POTTING RESIN USED TO ANCHOR THE MEMBRANES OF THE HEPARIN ADSORBER AND THE PLASMAFILTER HAEMOSELECT COMPONENTS OF THE SYSTEM.

Source documents

Other decisions for B. Braun Avitum AG

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.